Sahajanand Medical Technologies Limited is a global leader in medical device research, design, development, manufacturing, and marketing of vascular devices. Sahajanand Medical Technologies IPO will hit the market in December 2021.
Table of Contents
About Sahajanand Medical Technologies
In several segments, they set themselves apart by giving their clients high-quality solutions at market-competitive costs backed by solid clinical evidence.
With a market share of 21%, 25%, and 31% of the total DES sales volume in India in 2019, 2020, and 2021, respectively, as a result of this combination, they have a leading market share in the drug eluting stent (“DES”) market in India.
In each of Germany, the Netherlands, Italy, and Poland, they are one of the top five businesses in terms of market share (based on DES sales volume).
They sell directly and through distributors in over 69 nations, including direct sales in Germany, Poland, Spain, France, the United Kingdom, and Brazil.
Products
Currently, they provide items for interventional cardiology, including coronary stents and catheters, which are used to repair blockages in heart arteries (coronary artery disease).
Devices used to treat abnormalities in the tissues, walls, and valves of the heart, including transcatheter aortic valve implants (“TAVI”) and occluders, are examples of structural heart therapy.
Devices used to repair blockages in blood arteries other than the heart, including renal stents, are known as peripheral intervention.
Furthermore, as of the date of the DRHP, we had been issued 67 patents worldwide, with a pipeline of another 17 patents and four design registrations in India.
Journey
Mr. Dhirajlal Kotadia, a young lad who grew up in poverty, started their company. Mr. Kotadia was moved as an adult after seeing a destitute guy struggle to pay for his dying wife’s medications.
Mr. Kotadia was motivated by this occurrence to start a company that would focus on making vital life-saving goods more available to the general public, which led to the founding of our company in 2001.
Their company is motivated by their “Pledge to Save Millions” — millions of lives and millions of rupees for millions of families throughout the world.
Their firm became the first in the world to gain CE certification for a DES using a biodegradable polymer under Mr. Kotadia’s guidance.
Sahajanand Medical Technologies IPO
Sahajanand Medical Technologies Limited, headquartered in Mumbai has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 1,500 crores on 27 September 2021.
The offer includes 410.33 crores value fresh equity shares and there is an offer for sale (OFS) of INR 1,089.67 Crore value equity shares by the promoters mentioned in the DRHP. They are also looking to for pre-ipo placement of INR 185 crores.
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 861.95 | 631.78 | 520.37 | ||
| Total Revenue | 591.96 | 490.31 | 335.94 | ||
| Profit After Tax | (72.34) | 25.43 | 33.43 | ||
Basic and Diluted Earnings Per Share
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2021 | (8.13) | (8.13) | 3 |
| Financial Year 2020 | 2.76 | 2.69 | 2 |
| Financial Year 2019 | 4.00 | 3.67 | 1 |
| Weighted Average | (2.48) | (2.56) |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of the offer
The following are among the fundamental factors and key strengths that go into determining the Offer Price:
- In an industry with high entry barriers, technically sophisticated products are available.
- In India, they have a market-leading position in interventional cardiology, exploiting industry growth factors.
- They are booming in International marketplaces.
- Manufacturing capabilities that are both robust and efficient, resulting in excellent profits.
- R&D capabilities that have been proven.
- A steady and experienced leadership team is backed up by a highly competent workforce.
Sahajanand Medical Technologies IPO Peer Comparison
There are no publicly traded businesses in India that operate in a similar industry to theirs. As a result, providing an industry comparison in respect to their firm is not feasible.
Sahajanand Medical Technologies IPO Details
| IPO Opening Date | December 2021 |
| IPO Closing Date | December 2021 |
| Issue Type | Book Building |
| Face Value | 1 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | – |
| Min Order Quantity | – |
| Listing At | BSE, NSE |
| Issue Size | 1500 Crore |
| Fresh Issue | 410.33 crore |
| Offer for Sale | 1,089.67 Crore |
Sahajanand Medical Technologies IPO Date
Sahajanand Medical Technologies IPO opening date is December 2021, and the closing date is December 2021. The Sahajanand Medical Technologies IPO issue may list in December 2021.
| IPO Opening Date | December 2021 |
| IPO Closing Date | December 2021 |
| Basis of Allotment Date | December 2021 |
| Initiation of Refunds | December 2021 |
| Credit of Shares to Demat Account | December 2021 |
| IPO Listing Date | December 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 50 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 35 | Minimum level of 1 lot, based on availability, for every shareholder. |
Sahajanand Medical Technologies IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of SMT IPO.
Sahajanand Medical Technologies IPO GMP
Sahajanand Medical Technologies IPO Grey Market Premium is 0. You can check out GMP of Other IPOs on below Links:
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 | |||
| December 2021 |
Check Out the GMP of all Other IPOs
Sahajanand Medical Technologies IPO Review
Sahajanand Medical Technologies IPO review will depend on the price band which will be announced after SEBI approval. Whenever it will be announced we will update you regarding review of Sahajanand Medical Technologies IPO is good or bad.
Sahajanand Medical Technologies IPO Risk
- The COVID-19 pandemic’s long-term impact on their industry is unknown and unpredictable.
- They are subject to a slew of restrictions that might stymie their ability to promote their items.
- They are subject to variations in foreign currency exchange rates.
- Their inability to build or properly manage their expanding distribution network might be detrimental to their company.
- It’s possible that they won’t be able to protect their intellectual property rights all over the world.
- Their financing agreements compel them to adhere to certain restrictive covenants.
- They ‘ve been unable to discover some of their company’s historical documents.
- To commercialise their products in the United States, they require FDA permission or approval.
Other Threats
- The sale of a certain product accounts for the majority of their revenue.
- Any breakdown of our information technology systems might have a negative impact on our operations and company.
- Regulatory ambiguity around medical device pricing might have a negative impact on marketing, pricing, and demand for their goods.
- Their activities are governed by changing environmental, health, and safety rules and regulations.
- They work with dangers that have the potential to create severe health and safety risks on a regular basis.
- They, their competitors and 3rd parties perform clinical trials on their goods on a regular basis.
- Their company is involved in ongoing legal procedures. Any negative conclusion in such legal procedures might have an impact on their company.
Research & Development
They think that their continuing R&D efforts enable them to continue to develop new and technologically sophisticated items, while their operational scale allows them to make products that are affordable to the general public.
They are always working to improve their present goods and portfolio while also improving the efficiency of their manufacturing processes. They have three R&D centres: one in Surat, India, one in Galway, Ireland, and one in Nonthaburi, Thailand.
Their R&D efforts have resulted in the development of numerous significant vascular device innovations, including their biodegradable polymer in 2005 and their ultra-thin stent with a strut thickness of 60 microns.
Manufacturing Facilities
They have two production sites in India, in Surat and Bengaluru, where they make products for interventional cardiology and peripheral intervention, as well as one foreign location in Nonthaburi, Thailand, where they make structural heart treatment devices.
Their manufacturing infrastructure, they think, gives them a competitive edge since it helps them to keep product costs low while speeding up product creation and development.
In addition, to enhance their capacity and capabilities, they are constructing a new research, development, and manufacturing campus in Hyderabad, India. They intend to continue developing cutting-edge technical solutions.
Acquisition and Management
Through the purchase of Vascular Concepts and Vascular Innovations in 2020, they have extended their product range and entered the structural heart treatment market.
They gained access to Hydra TAVI, a novel transcatheter heart valve implant for treating severe aortic stenosis in high-risk patients, as a result of this purchase.
They aim to continue developing Hydra TAVI in order to broaden their total addressable market and access the rapidly increasing heart valve industry, which will be a key driver of future growth.
Their 11-member management team is competent and experienced, with an average tenure of eight years and experience ranging from ten to twenty years in their various fields of business.
Sahajanand Medical Technologies IPO Brokerage views
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Sahajanand Medical Technologies IPO Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| December 2021 | 1 | |||||
| December 2021 | 2 | |||||
| December 2021 | 3 |
Promoters
- Bhargav Dhirajlal Kotadia
- Shree Hari Trust
Promoter’s Holding
| Pre Issue Share Holding | 35.37% |
| Post Issue Share Holding |
Sahajanand Medical Technologies IPO Prospectus
Contact Details
Sahajanand Medical Technologies Limited
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta, Nani Ved, Ved Road,
Surat, Gujarat – 395 004, India
Tel: +91 261 6112800
E-mail: [email protected]
Website: www.smtpl.com
Registrar
Link Intime India Private Limited
C-101, 1st floor, 247 Park
Lal Bahadur Shastri Marg
Vikhroli (West)
Mumbai 400 083, Maharashtra, India
Tel: +91 22 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Lead Manager(s)
- UBS Securities India Private Limited
- Axis Capital Limited
- BofA Securities India limited
- Edelweiss financial services limited
We hope we are able to answer all your questions about Sahajanand Medical Technologies IPO. If you don’t have a Demat account, open it now with Zerodha best trading app of India.
Disclaimer
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms. We don’t endorse such activities at all. We are sticky against such activities & never advise anyone to trade in grey market at all.
FAQ
Sahajanand Medical Technologies IPO Opening Date?
Sahajanand Medical Technologies IPO will open in December 2021.
Sahajanand Medical Technologies IPO Listing Date?
Sahajanand Medical Technologies IPO will list in December 2021.
Sahajanand Medical Technologies IPO GMP Today?
Sahajanand Medical Technologies IPO Grey Market Premium is INR 0 .
Sahajanand Medical Technologies IPO Allotment Date?
Sahajanand Medical Technologies IPO basis of allotment will be in December 2021.
Lot size for Sahajanand Medical Technologies IPO?
Lot size for Sahajanand Medical Technologies IPO is 0.
